The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results
Abstract
BACKGROUND Empagliflozin, an SGLT2 inhibitor, has shown remarkable reductions in cardiovascular mortality and heart failure admissions (EMPA-REG OUTCOME). However, the mechanism underlying the heart failure protective effects of empagliflozin remains largely unknown. Cardiac fibroblasts play an integral role in the progression of structural cardiac remodelling and heart failure, in part, by regulating extracellular matrix (ECM) homeostasis. The objective of this study was to determine if empagliflozin has a direct effect on human cardiac myofibroblast-mediated ECM remodelling. METHODS Cardiac fibroblasts were isolated via explant culture from human atrial tissue obtained at open heart surgery. Collagen gel contraction assay was used to assess myofibroblast activity. Cell morphology and cell-mediated ECM remodelling was examined with the use of confocal microscopy. Gene expression of profibrotic markers was assessed with the use of reverse-transcription quantitative polymerase chain reaction. RESULTS Empagliflozin significantly attenuated transforming growth factor β1-induced fibroblast activation via collagen gel contraction after 72-hour exposure, with escalating concentrations (0.5 μmol/L, 1 μmol/L, and 5 μmol/L) resulting in greater attenuation. Morphologic assessment showed that myofibroblasts exposed to empagliflozin were smaller in size with shorter and fewer number of extensions, indicative of a more quiescent phenotype. Moreover, empagliflozin significantly attenuated cell-mediated ECM remodelling as measured by collagen fibre alignment index. Gene expression profiling revealed significant suppression of critical profibrotic markers by empagliflozin, including COL1A1, ACTA2, CTGF, FN1, and MMP-2. CONCLUSIONS We provide novel data showing a direct effect of empagliflozin on human cardiac myofibroblast phenotype and function by attenuation of myofibroblast activity and cell-mediated collagen remodelling. These data provide critical insights into the profound effects of empagliflozin as noted in the EMPA-REG OUTCOME study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Cardiac Fibrosis: The Fibroblast Awakens
Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E., & Blaxall, B. C. (2016) · Circulation Research · doi:10.1161/circresaha.115.306565 · Cited by 1,596
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart
Fu, X., Khalil, H., Kanisicak, O., Boyer, J. G., Vagnozzi, R. J., Maliken, B. D., Sargent, M. A., Prasad, V., Valiente-Alandi, I., Blaxall, B. C., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98215 · Cited by 636
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
Cardiac remodeling and failure
Fedak, P. W. M., Verma, S., Weisel, R. D., & Li, R.-K. (2005) · Cardiovascular Pathology · doi:10.1016/j.carpath.2005.01.005 · Cited by 120
Self-citation
Research works printed but not linked: 37
- Fitchett, 2017, A practical guide to the use of glucose-lowering agents with cardiovascular benefit or proven safety, Can J Cardiol, 33, 940
- Mancini, 2017, Diabetes for cardiologists: practical issues in diagnosis and management, Can J Cardiol, 33, 366
- Verma, 2018, Empagliflozin increases cardiac energy production in diabetes novel translational insights into the heart failure benefits of SGLT2 inhibitors, JACC Basic Transl Sci, 3, 575, 10.1016/j.jacbts.2018.07.006 · DOI · Paper page
- Lopaschuk, 2016, Empagliflozin’s fuel hypothesis: not so soon, Cell Metab, 24, 200, 10.1016/j.cmet.2016.07.018 · DOI
- Sattar, 2016, SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?, Diabetologia, 59, 1333, 10.1007/s00125-016-3956-x · DOI · Paper page
- Kaul, 2016, Is the mortality benefit with empagliflozin in type 2 diabetes mellitus too good to be true?, Circulation, 134, 94, 10.1161/CIRCULATIONAHA.116.022537 · DOI
- Ngu, 2014, Human cardiac fibroblast extracellular matrix remodeling: Dual effects of tissue inhibitor of metalloproteinase-2, Cardiovasc Pathol, 23, 335, 10.1016/j.carpath.2014.06.003 · DOI
- Teng, 2015, Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis, Am J Physiol Heart Circ Physiol, 308, H1564, 10.1152/ajpheart.00126.2015 · DOI
- Lijnen, 2003, Transforming growth factor-β1–mediated collagen gel contraction by cardiac fibroblasts, J Renin Angiotensin Aldosterone Syst, 4, 113, 10.3317/jraas.2003.011 · doi:10.3317/jraas.2003.011
- Kobayashi, 2005, TGF-β1 and serum both stimulate contraction but differentially affect apoptosis in 3D collagen gels, Respir Res, 6, 141, 10.1186/1465-9921-6-141 · DOI
- Souders, 2009, Cardiac fibroblast: the renaissance cell, Circ Res, 105, 1164, 10.1161/CIRCRESAHA.109.209809 · DOI · Paper page
- Kanisicak, 2016, Genetic lineage tracing defines myofibroblast origin and function in the injured heart, Nat Commun, 7, 1, 10.1038/ncomms12260 · DOI · Paper page
- Edgley, 2012, Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β, Cardiovasc Ther, 30, 30, 10.1111/j.1755-5922.2010.00228.x · DOI
- Kong, 2014, The pathogenesis of cardiac fibrosis, Cell Mol Life Sci, 71, 549, 10.1007/s00018-013-1349-6 · DOI · Paper page
- Kusaka, 2016, Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome, Cardiovasc Diabetol, 15, 1, 10.1186/s12933-016-0473-7 · DOI
- Habibi, 2017, Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes, Cardiovasc Diabetol, 16, 9, 10.1186/s12933-016-0489-z · DOI · Paper page
- Verma, 2016, Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?, Diabetes Care, 39, 1, 10.2337/dc16-1312 · DOI · Paper page
- Shi, 2017, Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?, Mol Cell Biochem, 433, 97, 10.1007/s11010-017-3018-9 · DOI
- Rajasekeran, 2016, Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis, Kidney Int, 89, 524, 10.1016/j.kint.2015.12.038 · DOI
- Heerspink, 2016, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications, Circulation, 134, 752, 10.1161/CIRCULATIONAHA.116.021887 · DOI · Paper page
- Baartscheer, 2016, Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits, Diabetologia, 60, 568, 10.1007/s00125-016-4134-x · DOI · Paper page
- Ye, 2017, SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor, Cardiovasc Drugs Ther, 31, 119, 10.1007/s10557-017-6725-2 · DOI · Paper page
- Ye, 2018, Dapagliflozin attenuates Na+/H+ exchanger-1 in cardiofibroblasts via AMPK activation, Cardiovasc Drugs Ther, 32, 553, 10.1007/s10557-018-6837-3 · DOI
- Maly, 2002, Critical role of protein kinase C α and calcium in growth factor induced activation of the Na+/H+ exchanger NHE1, FEBS Lett, 521, 205, 10.1016/S0014-5793(02)02867-3 · doi:10.1016/s0014-5793(02)02867-3
- Orlowski, 2004, Diversity of the mammalian sodium/proton exchanger SLC9 gene family, Pflugers Arch, 447, 549, 10.1007/s00424-003-1110-3 · DOI · Paper page
- Engelhardt, 2002, Inhibition of Na+/H+ exchange prevents hypertrophy, fibrosis, and heart failure in β1-adrenergic receptor transgenic mice, Circ Res, 90, 814, 10.1161/01.RES.0000014966.97486.C0 · DOI · Paper page
- Juneman, 2013, Development of a novel sodium-hydrogen exchanger inhibitor for heart failure, J Cardio Vasc Med, 1, 1
- Chen, 2016, Exercise attenuates intermittent hypoxia-induced cardiac fibrosis associated with sodium-hydrogen exchanger-1 in rats, Front Physiol, 7, 1, 10.3389/fphys.2016.00462 · DOI
- Castella, 2010, A new lock-step mechanism of matrix remodelling based on subcellular contractile events, J Cell Sci, 123, 1751, 10.1242/jcs.066795 · DOI
- Godbout, 2013, The mechanical environment modulates intracellular calcium oscillation activities of myofibroblasts, PLoS One, 8, e64560, 10.1371/journal.pone.0064560 · DOI
- Raizman, 2007, The participation of the Na+-Ca2+ exchanger in primary cardiac myofibroblast migration, contraction, and proliferation, J Cell Physiol, 213, 540, 10.1002/jcp.21134 · DOI
- Follonier, 2008, Myofibroblast communication is controlled by intercellular mechanical coupling, J Cell Sci, 121, 3305, 10.1242/jcs.024521 · DOI
- Zhou, 2017, Characterization and standardization of cultured cardiac fibroblasts for ex vivo models of heart fibrosis and heart ischemia, Tissue Eng Part C Methods, 23, 422, 10.1089/ten.tec.2017.0169 · DOI
- Santiago, 2010, Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts, Dev Dyn, 239, 1573, 10.1002/dvdy.22280 · DOI · Paper page
- Scheen, 2014, Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor, Clin Pharmacokinet, 53, 213, 10.1007/s40262-013-0126-x · DOI · Paper page
- Ndefo, 2015, Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes, P T, 40, 364
- Seman, 2013, Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects, Clin Pharmacol Drug Dev, 2, 152, 10.1002/cpdd.16 · DOI
Cited by
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Self-citationPathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
Self-citationSGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Metadata
- Authors
- Kang, S., Verma, S., Hassanabad, A. F., Teng, G., Belke, D. D., Dundas, J. A., Guzzardi, D. G., Svystonyuk, D. A., Pattar, S. S., Park, D. S. J., Turnbull, J. D., Duff, H. J., Tibbles, L. A., Cunnington, R. H., Dyck, J. R. B., & Fedak, P. W. M.
- Venue
- Canadian Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 36
- Issue
- 4
- Pages
- 543-553
- ISSN
- 0828-282X (ISSN-L)
- OpenAlex
- W2996517820
- Cited by
- 166
- References
- 7
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Canadian Institutes of Health Research
- Heart and Stroke Foundation of Canada
- Alberta Innovates - Health Solutions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. https://app.cochat.ai/papers/10.1016/j.cjca.2019.08.033
- The paper
- Kang, S., Verma, S., Hassanabad, A. F., Teng, G., Belke, D. D., Dundas, J. A., Guzzardi, D. G., Svystonyuk, D. A., Pattar, S. S., Park, D. S. J., Turnbull, J. D., Duff, H. J., Tibbles, L. A., Cunnington, R. H., Dyck, J. R. B., & Fedak, P. W. M. (2020). Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2019.08.033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.